Janssen, a subsidiary of Johnson & Johnson, has entered a license agreement with Vedanta Biosciences to develop the latter firm's lead microbiome pharmaceutical candidate, VE202, for inflammatory bowel disease (IBD).
The deal, which was facilitated by the Johnson & Johnson Innovation Center in Boston, will see Janssen take over development...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
